Oep Philippines

What Oep Philippines does

OEP Philippines is a wholly-owned regional sales and marketing subsidiary of Orient EuroPharma Co., Ltd. (友華生技醫藥股份有限公司), a Taiwan-OTC-listed (ticker 4120) multinational pharmaceutical group founded in 1982 and headquartered in Taipei. Established in 2003 through acquisition of a Philippine pharmaceutical entity, OEP Philippines markets prescription drugs and medical aesthetics products through direct sales teams and pharmacy channels, serving healthcare providers (hospitals, clinics, physicians) and patients. The subsidiary ranked 50th among IQVIA Philippines total pharma companies in Q2 2022 and is one of nine country operations (alongside Taiwan, Singapore, Malaysia, Vietnam, Indonesia, China, Hong Kong, New Zealand, and USA) within the OEP group.

The parent group's product portfolio spans prescription pharmaceuticals (cardiovascular, oncology, neurology, respiratory, metabolic, dermatology), innovative medical devices (TissueTech amniotic membrane products), consumer health (Karihome infant goat milk formula co-developed with New Zealand Dairy Goat Co-operative, Babecare, Nutrifuel), and medical aesthetics (ISISPHARMA dermo-cosmetics, Bio-Oil, Cumlaude Lab, AGLab, Hyabell hyaluronic acid fillers, Nabota botulinum toxin). Core technology includes a proprietary Multi-Level Drug Release Technology (MPRT) platform combining hot-melt, osmotic, and microparticle control release technologies, with sterile injectable manufacturing compliant with FDA, PIC/S GMP, and EU GMP standards at subsidiaries 友霖生技 (Youlin Bio-Tech, oral solid dose) and 友杏生技 (Youxing Biotechnology, sterile injectable/oncology).

The group monetizes through one-time sales of prescription and consumer products across multiple categories, professional services via CMO/CDMO contracts, and royalty/licensing arrangements with international partners including Maruho, Rakuten Medical, Chiesi, Oncuest, Rovi, CBL-Medtech, and Kissei. Direct sales teams target healthcare institutions while pharmacy and retail channels handle consumer health and aesthetics products. Recent 2022-2026 partnerships have aggressively expanded the specialty/oncology/rare disease pipeline, though no Philippines-segment revenue is publicly disclosed.

Name

Oep Philippines

Legal name

友華生技醫藥股份有限公司

Website

https://oepgroup.com

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

101–250 employees

Short description

OEP Philippines is a Manila-based sales and marketing subsidiary of Taiwan-listed Orient EuroPharma (4120.TW), marketing prescription pharmaceuticals (cardiovascular, oncology, respiratory) and medical aesthetics products to hospitals, clinics, physicians, and pharmacies across the Philippines.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Hand & Body Care (Lotions, Creams, Body Oils) (CRADANAC), Vitamins & Minerals (Single Nutrients) (CRADAGAB)

Keywords

• Prescription pharmaceuticals
• Medical aesthetics
• Cardiovascular drugs
• Oncology medications
• Pharmaceutical distribution

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Prescription Pharmaceuticals: Prescription drugs including cardiovascular, oncology, respiratory, neurology, and metabolic medications sold through direct sales channels in Taiwan and overseas markets
2. Nutritional Health Products: Infant formula (goat and cow milk), adult nutritional supplements, and healthcare products distributed through pharmacies and retail channels
3. Medical Aesthetics: Dermatological products, injectable hyaluronic acid, skincare products, and medical devices for aesthetic treatments
4. CMO/CDMO Services: Contract manufacturing and development services for pharmaceutical products using oral and injectable manufacturing capabilities

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

OEP Philippines markets and distributes a portfolio of prescription pharmaceuticals and medical aesthetics products to healthcare providers and consumers in the Philippines. Established in 2003 as a wholly-owned subsidiary of Orient EuroPharma, the company runs direct sales teams serving hospitals, clinics, and physicians with cardiovascular, oncology, respiratory, neurology, and metabolic drugs, while also distributing dermatological products, hyaluronic acid injectables, and skincare lines through pharmacies and aesthetic clinics.

Product overview

Oep Philippines (Orient EuroPharma/友華生技) operates as a multinational pharmaceutical company with three integrated business segments: (1) Prescription Pharmaceuticals covering cardiovascular, oncology, neurology, immunology, infectious disease, gynecology, respiratory, metabolic, dermatology, andrology, and weight management medications; (2) Innovative Medical devices including TissueTech ophthalmic products; (3) Consumer Health comprising infant nutrition brands (Karihome goat milk formula as market leader with ~70% Taiwan share, Babecare), adult nutrition (Nutrifuel), and medical aesthetics (ISISPHARMA skincare, Bio-Oil, Cumlaude Lab feminine care, AGLab anti-aging, HA fillers, botulinum toxin injections). The company has vertically integrated manufacturing through subsidiaries Youben Biotech and Youxing Biotech, with R&D centers in Taiwan and USA.

Differentiator

Problem solved

Functional benefit

Brands

• 卡洛塔妮 (Karihome): 紐西蘭原裝進口嬰幼兒羊奶粉品牌，與紐西蘭羊奶合作社(DGC)共同開發，全球第一罐嬰幼兒羊奶粉品牌，領導品牌
• 貝比卡兒 (Babecare)
• 愛斯康 (Nutrifuel)
• 伊姿法瑪 (ISISPHARMA)
• 百洛 (Bio-Oil)
• 珂瑈 (Cumlaude Lab)
• 恆妍肌 (AGLab)
• TissueTech

Products and services

• Prescription Cardiovascular Drugs Cardiovascular medications distributed by OEP Philippines, including lipid-control agents, antihypertensives, and diuretics, sold to hospitals, clinics, and physicians in the Philippines for cardiovascular disease management.
• Prescription Oncology Drugs Oncology medications distributed by OEP Philippines for lung, breast, prostate, multiple myeloma, and hematologic cancers, including oral and IV formulations and supportive-care antiemetics, sold to oncology specialists and hospitals in the Philippines.
• Prescription Respiratory Drugs Asthma and COPD medications distributed by OEP Philippines for respiratory disease management, sold to pulmonologists and hospitals in the Philippines.
• Prescription Neurology Drugs Neurology medications including epilepsy treatments and ADHD therapies distributed by OEP Philippines to neurologists, psychiatrists, and hospitals in the Philippines.
• Prescription Metabolic Drugs Metabolic disease medications including lipid-lowering agents and diabetes-related therapies distributed by OEP Philippines to endocrinologists and hospitals in the Philippines.
• Medical Aesthetic Injectables Dermatological injectables and hyaluronic acid fillers distributed by OEP Philippines to dermatologists and aesthetic clinics in the Philippines for cosmetic and skin-rejuvenation procedures.
• Medical Aesthetic Skincare Products Professional dermatological skincare products distributed by OEP Philippines through pharmacies and aesthetic clinics in the Philippines for skin condition management and aesthetic enhancement.

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Kissei Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 5 May 2026Exclusive development and commercialization rights for Olutasidenib in Taiwan for acute myeloid leukemia (AML) treatment. Olutasidenib is an IDH1 inhibitor developed by Rigel Pharmaceuticals, FDA-approved in 2022.
• Maruho Co., Ltd.coreStrategic or Co-development Partner · 22 January 2026Strategic collaboration with Japanese dermatology leader Maruho for Rapifort prescription drug rights in Taiwan. Maruho is a Japanese pharmaceutical company established in 1915 specializing in dermatology. The partnership expands OEP's dermatology prescription drug portfolio with products for primary axillary hyperhidrosis treatment.
• Rakuten Medical, Inc. (樂天醫藥)coreStrategic or Co-development Partner · 27 June 2025Exclusive licensing agreement with Rakuten Medical for Alluminox platform photoimmunotherapy products in Taiwan, Malaysia, Singapore, and Philippines. The partnership involves co-development and commercialization of cancer treatment using light-activated drug technology. OEP subsidiary Cyntec will lead regulatory and commercial activities in licensed regions.
• B.L. HUAminorChannel Partner/ Reseller/ Distributor · 14 September 2023Distribution partnership with Thai pharmaceutical company for Methydur ADHD medication in Thailand. B.L. HUA is a 100-year-old company specializing in neuropsychiatric medications.
• 昂瑞生物醫藥技術有限公司 (Oncuest Biotech)coreStrategic or Co-development Partner · 29 March 2023Partnership with Shenzhen Hepalink subsidiary for Oregovomab late-stage ovarian cancer immunotherapy drug rights in Taiwan. Oregovomab is a first-in-class anti-CA125 monoclonal antibody candidate. USD 11.2 million deal for exclusive Taiwan agency rights plus priority for Hong Kong and Macau.
• Chiesi Global Rare DiseasescoreStrategic or Co-development Partner · 25 October 2022Exclusive distribution rights for three rare disease enzyme replacement therapies in Taiwan and Southeast Asia: Revcovi (ADA-SCID), Lamzede (Alpha-Mannosidosis), and PRX-102 (Fabry Disease). Chiesi is an Italian pharmaceutical group with over 85 years of history.
• 瓴路愛迪思 (Ludu ADC)coreStrategic or Co-development Partner · 12 July 2022Exclusive distribution rights for Loncastuximab tesirine (ADC drug for复发/难治性弥漫大B细胞淋巴瘤) in Taiwan and Singapore. Partnership addresses significant unmet clinical needs for lymphoma patients.
• Laboratorios Farmacéuticos Rovi, S.A.coreStrategic or Co-development Partner · 9 May 2022Exclusive rights for long-acting schizophrenia injection in Taiwan and Hong Kong. Rovi has ISM technology platform for long-acting injectables and is a COVID-19 vaccine supplier.
• KUHNIL PHARMAminorChannel Partner/ Reseller/ Distributor · 7 March 2022Distribution partnership with Korean pharmaceutical company for lipid-lowering combination drug in South Korea. KUHNIL focuses on neuropsychiatry, cardiovascular, and gastroenterology.
• 康霈生技 (CBL-Medtech)coreStrategic or Co-development Partner · 1 September 2021NT$168 million investment for CBL-514 lipolysis injection exclusive sales rights in Taiwan. CBL-514 is a first-in-class lipolysis injection drug targeting the NT$100 billion+ medical aesthetics market.
• Dairy Goat Co-operative (DGC)coreStrategic or Co-development Partner · 1 September 2021Co-owned brand partnership with DGC for Karihome infant goat milk formula. DGC is a New Zealand cooperative of 72 farms. OEP owns goat farms in New Zealand and produces Karihome products in partnership with DGC.
• 永昕生物醫藥 (Liyen Biotech)coreStrategic or Co-development Partner · 28 December 2016Southeast Asia distribution partnership for TuNEX rheumatoid arthritis biologic drug. Rights covered Philippines, Vietnam, Malaysia, Thailand, Singapore, Myanmar, Brunei, Cambodia, and Laos.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• TTY Biopharm: Taiwan-listed specialty pharmaceutical company with similar mid-cap scale, oncology and specialty drug focus, and international expansion into Southeast Asia. Highly comparable in product mix (prescription drugs across multiple therapeutic areas), regional presence, and Taiwan OTC listing.
• Center Laboratories: Taiwan pharmaceutical company with both prescription pharmaceutical manufacturing and consumer nutrition/infant formula businesses — closely matching OEP's hybrid pharma + nutrition model (e.g., Karihome goat milk formula parallel).
• Yung Shin Pharmaceutical: Established Taiwan pharmaceutical company with similar diversified prescription drug portfolio spanning multiple therapeutic areas and consumer health products. Comparable mid-cap scale and Asia-Pacific distribution approach.
• Standard Chemical & Pharmaceutical: Taiwan pharmaceutical manufacturer of similar scale covering multiple therapeutic areas including cardiovascular and central nervous system. Comparable mid-cap Taiwan pharma business profile with diversified prescription product portfolio.
• TWi Pharmaceuticals: Taiwan-based specialty and generic pharmaceutical company with oncology and CNS focus. Comparable size and business model with emphasis on 505(b)(2) reformulations and international markets.

Regional players

• Kalbe Farma: Indonesia's largest pharmaceutical company with prescription drugs, consumer health, nutrition, and distribution across Southeast Asia. Comparable broad healthcare conglomerate structure with strong regional brand portfolio and overlapping Southeast Asia geographies.
• Mega Lifesciences: Thailand-headquartered pharmaceutical and consumer health company with deep Southeast Asia distribution. Comparable hybrid model spanning prescription pharma, nutraceuticals, and consumer personal care; serves as a regional Southeast Asia peer with overlapping markets (Philippines, Vietnam, Malaysia).

Others

• DKSH Holding: Switzerland-listed market expansion services company specializing in pharmaceutical and consumer goods distribution across Asia-Pacific. Adjacent business model overlap (regional distribution of healthcare products in Southeast Asia) makes it relevant for understanding OEP Philippines' go-to-market motion and partnership economics.

Broad incumbents

• Taisho Pharmaceutical: Major Japanese pharmaceutical company with established OTC, prescription, and consumer healthcare businesses across Asia. Broader incumbent peer with overlapping dermatology/aesthetics and OTC consumer health positioning; larger scale provides comparison for OEP's premium consumer brands strategy.

Emerging players

• TOT Biopharm: Smaller Taiwan-listed specialty biopharmaceutical company with oncology and specialty drug focus. Comparable in oncology pipeline development and Taiwan listing, though smaller scale and more emerging-stage pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/IsispharmaTaiwan

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oep Philippines